Fulgent Genetics, Inc. (FLGT) Investor Relations Documents

Fulgent Genetics, Inc. (FLGT) investor relations documents from the company's IR site: 3 presentations, 34 press releases; latest deck 2026-07-30. Read in-app with summaries. First-party data.

Fulgent Investor Presentation: Fulgent Genetics (NASDAQ: FLGT) is a global genetic testing company reporting $85M in Q2 2026 revenue, a 4% year-over-year increase.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-30PresentationFulgent Investor Presentation
2026-07-30Press releaseFulgent Reports Second Quarter 2026 Financial Results
2026-07-09Press releaseFulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
2026-06-01Press releaseFulgent Presents Updated FID-007 Data at ASCO 2026
2026-05-21Press releaseFulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the
2026-05-01Press releaseFulgent Reports First Quarter 2026 Financial Results
2026-04-22Press releaseFulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Me
2026-04-16Press releaseFulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
2026-03-17Press releaseFulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
2026-02-27Press releaseFulgent Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-12Press releaseFulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Press releaseFulgent Reports Third Quarter 2025 Financial Results
Press releaseFulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
Press releaseFulgent Reports Second Quarter 2025 Financial Results
Press releaseFulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
Press releaseFulgent Reports First Quarter 2025 Financial Results
2025-02-28Press releaseFulgent Reports Fourth Quarter and Full Year 2024 Financial Results
2024-11-08Press releaseFulgent Reports Third Quarter 2024 Financial Results
2024-08-02Press releaseFulgent Reports Second Quarter 2024 Financial Results
2024-05-03Press releaseFulgent Reports First Quarter 2024 Financial Results
2024-02-28Press releaseFulgent Reports Fourth Quarter and Full Year 2023 Financial Results
2023-11-03Press releaseFulgent Reports Third Quarter 2023 Financial Results
2023-08-04Press releaseFulgent Reports Second Quarter 2023 Financial Results
2023-05-05Press releaseFulgent Reports First Quarter 2023 Financial Results
2023-03-07PresentationFulgent Investor Presentation
2023-02-28Press releaseFulgent Reports Fourth Quarter and Full Year 2022 Financial Results
2022-11-07Earnings deckFulgent Pharma Acquisition Announcement
2022-11-07Press releaseFulgent Genetics Reports Third Quarter 2022 Financial Results
2022-08-04Press releaseFulgent Genetics Reports Second Quarter 2022 Financial Results
2022-05-03Press releaseFulgent Genetics Reports First Quarter 2022 Financial Results
2022-02-23Press releaseFulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
2021-11-09Press releaseFulgent Genetics Reports Third Quarter Financial Results
2021-08-09Press releaseFulgent Genetics Reports Second Quarter Financial Results
2021-05-06Press releaseFulgent Genetics Reports Record First Quarter Financial Results
2021-03-04Press releaseFulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
Press releasePac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics Partnership
Press releaseFulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

FLGT overview · FLGT earnings · FLGT financials · FLGT KPIs · FLGT documents · FLGT ownership · FLGT peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.